Global Cellular and Gene Therapy CDMO Market Size By Service Type, By Product Type, By End-User, By Geographic Scope And Forecast

Cellular and Gene Therapy CDMO Market Size And Forecast

Cellular and Gene Therapy CDMO Market size was valued at USD 2.5 Billion in 2023 and is projected to reach USD 24.5 Billion by 2030, growing at a CAGR of 22.2% during the forecast period 2024-2030.

Global Cellular and Gene Therapy CDMO Market Drivers

The growth and development of the Cellular and Gene Therapy CDMO Market is attributed to certain main market drivers. These factors have a big impact on how Cellular and Gene Therapy CDMO are demanded and adopted in different sectors. Several of the major market forces are as follows

• Expanding Pipeline of Gene and Cell treatments The need for CDMO services is driven by the growing pipeline of gene and cell treatments in various phases of research, including clinical trials. Companies in the biopharmaceutical industry frequently work with CDMOs to take advantage of their infrastructure and experience in development and production.
• Growing Public and Private Sector Investments in Cellular and Gene Therapy Research The market is expanding as a result of growing public and private sector investments in cellular and gene therapy research and development. Funding helps treatments move from the discovery stage to clinical development, which gives CDMOs opportunities.
• Developments in Gene Editing Technologies The creation of gene treatments has been expedited by the ongoing development of gene editing technologies like CRISPR-Cas9, TALENs, and zinc finger nucleases. The production of gene-edited cellular products is a critical function of CDMOs, which in turn drives demand for their services.
• Growing Prevalence of Genetic abnormalities The creation of gene therapies is fueled by the rising incidence of uncommon diseases and genetic abnormalities. The ability to manufacture customized treatments that target particular genetic defects is provided by CDMOs.
• FDA Approvals and Regulatory Support An obvious route for commercialization has been made possible by a surge in regulatory approvals for cellular and gene therapies, such as CAR-T cell therapies. In order to achieve quality and compliance criteria, biopharmaceutical companies are encouraged to work with CDMOs through regulatory support.
• Industry Collaboration and Partnerships The sharing of knowledge, resources, and infrastructure is facilitated by collaboration between CDMOs and biopharmaceutical companies. Companies may develop and produce cellular and gene therapies more quickly thanks to partnerships.
• Growing Adoption of Autologous Therapies Using a patient’s own cells, autologous cellular therapies are becoming more and more common. Personalized autologous therapy production depends on CDMOs, which fuels industry expansion.
• Emerging Technologies in the Manufacturing of Cell treatments Automation and closed-system bioreactors are two examples of how manufacturing technologies for cell treatments are always being improved and innovated to increase scalability and efficiency. When CDMOs use these technology, biopharmaceutical companies find them to be appealing partners.

Global Cellular and Gene Therapy CDMO Market Restraints

The Cellular and Gene Therapy CDMO Market has a lot of room to grow, but there are several industry limitations that could make it harder for it to do so. It’s imperative that industry stakeholders comprehend these difficulties. Among the significant market limitations are

• Complicated Manufacturing Procedures Gene and cellular therapies sometimes require intricate manufacturing procedures, which can be difficult and resource-intensive. The complexity of creating these treatments can cause CDMOs to incur more expenses and lead longer lead times.
• High Development and Manufacturing Costs The creation and production of gene and cellular therapies necessitate large capital expenditures for specialized infrastructure, machinery, and knowledgeable staff. Both CDMOs and their clients may be limited by the high expenses connected to these activities.
• Regulatory Challenges Adherence to strict regulatory criteria is crucial, as the regulatory environment surrounding gene and cellular therapies is always changing. For CDMOs, adhering to regulatory requirements and negotiating the regulatory approval process can be difficult and time-consuming, which can impact project timeframes.
• Limited Standardization in Manufacturing Variability in production techniques may result from the absence of defined platforms and processes for cellular and gene therapies. The absence of standards could make it difficult to achieve scalability and uniform product quality.
• Scalability Issues It can be difficult to move from small-scale clinical studies to commercial-scale manufacture of cellular and gene treatments. One major constraint is achieving scalability while upholding regulatory norms and product quality.
• Supply Chain Risks Gene and cellular therapies can entail intricate supply chains that include acquiring raw materials, planning, and shipping. Disruptions in the supply chain have the potential to affect and delay the production process.
• Limited Commercialization of Therapies There are currently only a few commercially available cellular and gene therapies, and many are still in the early phases of clinical development. This could limit the total need for CDMO services.
• Scientific and Technological Challenges It may be difficult for CDMOs to stay up to date with the most recent advancements due to the rapid advances in science and technology. It can be difficult to adopt new technology and remain at the forefront of scientific understanding.

Global Cellular and Gene Therapy CDMO Market Segmentation Analysis

The Global Cellular and Gene Therapy CDMO Market is Segmented on the basis of Service Type, Product Type, End-User, and Geography.

1. By Service Type

• Development Services These include process development, early-stage development, and product optimization for gene and cellular therapy.
• Manufacturing Services Including the large-scale production, assembly, and quality assurance of gene and cellular therapies in preparation for market release and clinical trials.
• Additional Services These comprise supply chain management, logistics, regulatory assistance, and analytical testing.

2. By Product Type

• Viral Vectors CDMOs engaged in the research and production of lentiviral and adeno-associated vectors (AAVs), which are utilized in gene treatments.
• Plasmid DNA This includes services pertaining to the synthesis of plasmid DNA for use in gene therapy.
• Cell-based Products This category includes services related to the creation and production of different cell-based treatments.

3. By End-User

• Pharmaceutical and Biotechnology Companies For efficiency and knowledge, these businesses outsource their development and production work to CDMOs.
• Academic and Research Institutions Working with CDMOs on preclinical development and research-focused projects.
• Contract Research Organizations (CROs) Businesses that offer full-service gene and cellular therapy under contract.

4. By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East, and Africa

Key Players

The major players in the Cellular and Gene Therapy CDMO Market are

• Lonza (Switzerland)
• Catalent (USA)
• Charles River Laboratories (USA)
• The Discovery Labs (USA)
• WuXi AppTec (China)
• Exothera (USA)
• BIOCENTRIQ (Switzerland)
• FUJIFILM Diosynth Biotechnologies (UK)

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any  please connect with our sales team, who will ensure that your requirements are met.